Fact CheckerSign in

NCT05523375Completed

Promoting Successful Weight Loss in Primary Care in Louisiana Using Information Technology

Source: ClinicalTrials.gov · Last updated 17 Sept 2026

Brief summary (registry, in English)

The primary aim is to test the effectiveness of an innovative 24-month pragmatic and scalable weight-loss centric approach using a collaborative care model that connects patients with a non-Primary Care Practitioner (PCP) health coach who delivers care remotely to patients through the patient portal of an electronic medical record (EMR).

Status (registry)
Completed
Study type
Interventional
Enrollment
352 (actual)
First submitted
29 Aug 2022
Start date
29 Aug 2022
Primary completion date
28 Feb 2026
Lead sponsor
Pennington Biomedical Research Center
NCT number
NCT05523375

What you commit to

  • Study type: Interventional
  • Participants enrolled: 352
  • From 29 Aug 2022 to the primary completion date, 28 Feb 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Current use of weight loss medication or recent weight loss (net loss \>10 lbs in the last six months)
  • Past bariatric surgery or plans for bariatric surgery within 2 years

Other illness

  • Disease/condition that is life threatening or can interfere with or be aggravated by exercise or weight loss

Other

  • Body weight ≥ 400 lbs.
  • Currently participating in a structured weight loss program
  • Plans to move from the area within 2 years
  • Given birth within the past year, is currently pregnant or breastfeeding or plans to become pregnant within 2 years

Who the study is looking for

  • 40-70 years of age
  • Self-identify as Black/African American
  • Obesity (BMI 30.0-50.0 kg/m2)
  • Type II diabetes (based on ICD-10 codes, fasting plasma glucose ≥126 mg/dL, HbA1c ≥6.5%, 2-h plasma glucose during 75-g Oral Glucose Tolerance Test (OGTT) ≥200 mg/dL, or a random plasma glucose ≥200 mg/dL in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis) or pre-diabetes (based on ICD-10 codes, fasting glucose 100-125 mg/dL or HbA1c 5.7-6.4% or 2-h glucose during 75-g OGTT 140-199 mg/dL)
  • Has an internet-connected device and is willing to use it for intervention delivery
  • Patient in the Ochsner Health System with an active MyOchsner portal account, or willing to create one
  • Acknowledgement from their Ochsner primary care practitioner that there are no known contraindications to the patient's participation
  • Have weight measured at an Ochsner clinic within 4 weeks of screening
  • Resident of Louisiana
  • Be able to provide informed consent
  • Willing to change diet and/or physical activity

Age in the registry: 40 years to 70 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Pennington Biomedical Research Center
Coordinator of this site? Confirm its status
Baton RougeUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.